| Revenue growth | +20% YoY; ₹15,600 Mn in Q2FY27 |
|---|---|
| Margins | Gross margin 64.4%, -134 bps YoY; EBITDA margin 21.6%, +19 bps YoY |
| Demand visibility | Strong filings momentum; 26 ANDAs pending; US TAM ~$35Bn |
| Management confidence | Constructive; cost pressures to persist, passed to customers with lag |
Growth
Revenue +20% YoY: FD +18%, API +23%, PFI +20%, CDMO +77%. Europe +65%, North America +14%. PAT +39% YoY.
Outlook
No explicit numeric FY27 guidance. ~₹20,000 Mn organic capex over 3–4 years; 3 potential sole first-to-file ANDAs filed.
Risks
Gross margin -134 bps YoY to 64.4% on West Asia input costs. Peptide CDMO EBITDA loss ₹152 Mn. Gagillapur EIR awaited.
Investor Presentation filed with NSE, NSE: GRANULES. Summary written with AI assistance from the document.
Granules India Ltd: key numbers
- Share price
- ₹821.95
- Market cap
- ₹20,368 Cr
- Revenue (annual)
- ₹5,366 Cr
- Net profit (annual)
- ₹595.0 Cr
- P/E (TTM)
- 30.8×Sector 45.9×
- Promoter holding
- 37.39%-0.63% QoQ
- FII holding
- 20.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Granules India Ltd
All →Granules India Earnings Call Transcript: Key Takeaways
Q2 revenue ₹1,560 Cr (+20% YoY) and PAT ₹182 Cr (+39%), but EBITDA margin fell 131bps QoQ on West Asia costs. Gagilapur FDA observations leave the warning letter unresolved.
Granules India Other Announcement
Granules India submitted its monitoring agency report on preferential issue proceeds for quarter ended September 2026. It reports no deviation from stated objects.
Granules India Results Update
Granules India reported Q2FY27 revenue of INR 15,600 Mn, up 20% YoY, and PAT of INR 1,818 Mn, up 39%. The company also cited a net cash position and a US FDA audit at its Gagillapur site.
Granules India Q2 FY27 Results: Net Profit ₹181.8 Cr, Up 39.2% YoY
Granules India Ltd reported revenue from operations of ₹1,560 Cr (+20.3% YoY) and net profit of ₹181.8 Cr (+39.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹181.8 Cr · +39.2% YoY
Granules India Business Update
Granules' Gagillapur facility received eleven USFDA observations with no impact on product supply. The inspection was the first since a February 2025 Warning Letter.
Granules India Convertible Warrants
Chigurupati family promoters disclosed acquiring 2,49,82,906 warrants via preferential allotment on 23 February 2026. Warrants priced at ₹585 each lift diluted promoter-group holding to 43.69%.
- Value
- ₹1,462 Cr